{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:41:28Z","timestamp":1790293288025,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jmoldx.2021.07.026","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T11:40:34Z","timestamp":1629891634000},"page":"1422-1432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Molecular Testing in Breast Cancer"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7543-1532","authenticated-orcid":false,"given":"Lulu","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5232-9663","authenticated-orcid":false,"given":"Ariel","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2866-8283","authenticated-orcid":false,"given":"Gregory R.","family":"Bean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian S.","family":"Hagemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4269-3234","authenticated-orcid":false,"given":"Chieh-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2021.07.026_bib1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1126\/science.168640","article-title":"Predicting response to endocrine therapy in human breast cancer: a hypothesis","volume":"189","author":"Horowitz","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib2","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3389\/fphar.2017.00620","article-title":"Tamoxifen from failed contraceptive pill to best-selling breast cancer medicine: a case-study in pharmaceutical innovation","volume":"8","author":"Quirke","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib3","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib4","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib5","doi-asserted-by":"crossref","first-page":"815","DOI":"10.5858\/arpa.2016-0051-RA","article-title":"Molecular testing in breast cancer: a guide to current practices","volume":"140","author":"Hagemann","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/his.12795","article-title":"Biomarker assessment and molecular testing for prognostication in breast cancer","volume":"68","author":"Kos","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib7","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib8","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib9","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib10","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib11","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer","volume":"373","author":"Sparano","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib14","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.2015.63.5383","article-title":"West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment","volume":"34","author":"Gluz","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib15","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12885-018-4331-8","article-title":"The 21-gene Recurrence Score\u00ae assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)","volume":"18","author":"Penault-Llorca","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib16","series-title":"First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy +\/- chemotherapy in patients with 1-3 positive nodes, hormone receptor-positive and HER2-negative breast cancer with recurrence score <25: SWOGS1007 (RxPonder)","first-page":"GS3-00","author":"Kalinsky","year":"2020"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.2007.14.3222","article-title":"Clinical application of the 70-gene profile: the MINDACT trial","volume":"26","author":"Cardoso","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib18","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.3747\/co.24.3595","article-title":"Clinical utility of multigene profiling assays in early-stage breast cancer","volume":"24","author":"Chang","year":"2017","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib19","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","article-title":"70-Gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","volume":"22","author":"Piccart","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12920-015-0129-6","article-title":"Development and verification of the PAM50-based Prosigna breast cancer gene signature assay","volume":"8","author":"Wallden","year":"2015","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib22","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/annonc\/mdv215","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib23","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/jnci\/djt244","article-title":"Factors predicting late recurrence for estrogen receptor-positive breast cancer","volume":"105","author":"Sestak","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib24","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-13-1845","article-title":"The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer","volume":"20","author":"Filipits","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib25","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1200\/JCO.2014.55.6894","volume":"33","author":"Sestak","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10549-014-3259-1","article-title":"Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial","volume":"149","author":"Liu","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib27","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1158\/1078-0432.CCR-07-5026","article-title":"A five-gene molecular grade index and HOXB13.IL17BR are complementary prognostic factors in early stage breast cancer","volume":"14","author":"Xiao-Jun","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib28","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/bcr3402","article-title":"HOXB13: IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease","volume":"15","author":"Habel","year":"2013","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib29","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djt146","article-title":"Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13\/IL17BR biomarker","volume":"105","author":"Sgroi","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib30","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdz289","article-title":"Breast cancer index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen\u2014To Offer More? (aTTom) trial","volume":"30","author":"Bartlett","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/1078-0432.CCR-20-2737","article-title":"Breast cancer index predicts extended endocrine benefit to individualize selection of patients with HR\u00fe early-stage breast cancer for 10 years of endocrine therapy","volume":"27","author":"Noordhoek","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib32","first-page":"162","article-title":"Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast","volume":"41","author":"Correa","year":"2010","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib33","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jnci\/djt067","article-title":"A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast","volume":"105","author":"Solin","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib34","doi-asserted-by":"crossref","first-page":"djw256","DOI":"10.1093\/jnci\/djw256","article-title":"Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in situ","volume":"109","author":"Rakovitch","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib35","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-18-0842","article-title":"A biological signature for breast ductal carcinoma in situ to predict radiotherapy benefit and assess recurrence risk","volume":"24","author":"Bremer","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib36","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1158\/1078-0432.CCR-19-1152","article-title":"Validation of a ductal carcinoma in situ biomarker profile for risk of recurrence after breast-conserving surgery with and without radiotherapy","volume":"26","author":"Weinmann","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib37","series-title":"AJCC Cancer Staging Manual (8th Edition)","year":"2017"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib38","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S1470-2045(13)70387-5","article-title":"Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population","volume":"14","author":"Sgroi","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib39","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1200\/JCO.2012.42.1990","article-title":"Recognition and handling of discordant negative human epidermal growth factor receptor 2 classification by Oncotype DX in patients with breast cancer","volume":"30","author":"Christgen","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/tbj.12223","article-title":"ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment","volume":"20","author":"Park","year":"2014","journal-title":"Breast J"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib41","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1200\/JCO.2011.34.7963","article-title":"High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study","volume":"29","author":"Dabbs","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib43","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1245\/s10434-014-3908-y","article-title":"Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)","volume":"21","author":"Whitworth","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib44","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib45","doi-asserted-by":"crossref","first-page":"31347","DOI":"10.18632\/oncotarget.15532","article-title":"Expression of PD-L1 and prognosis in breast cancer: a metaanalysis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib46","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib47","first-page":"LBA16","article-title":"IMpassion130: final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreat... | OncologyPRO","volume":"2020","author":"Emens","year":"2020","journal-title":"ESMO Virtual Congr"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib48","doi-asserted-by":"crossref","first-page":"S1142","DOI":"10.1016\/j.annonc.2020.08.2243","article-title":"Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) \u00b1 atezolizumab (atez... | OncologyPRO","volume":"31","author":"Miles","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib49","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10549-019-05438-y","article-title":"Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort","volume":"179","author":"Cheng","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib51","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s41591-019-0582-4","article-title":"Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study","volume":"25","author":"Staaf","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib52","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1053\/j.semdp.2019.06.002","article-title":"Pitfalls in molecular diagnostics","volume":"36","author":"Sun","year":"2019","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib53","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib54","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1200\/JCO.2020.38.15_suppl.1013","article-title":"Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119","volume":"38","author":"Winer","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib55","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor\u2013positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib56","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jmoldx.2019.03.008","article-title":"Detection of tumor NTRK gene fusions to identify patients who may benefit from tyrosine kinase (TRK) inhibitor therapy","volume":"21","author":"Hsiao","year":"2019","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib57","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib58","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1535-6108(02)00180-0","article-title":"Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma","volume":"2","author":"Tognon","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib59","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS17-P2-09-15","article-title":"Abstract P2-09-15: NTRK fusions in breast cancer: clinical, pathologic and genomic findings","volume":"78","author":"Ross","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib60","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/PAS.0000000000000911","article-title":"Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions","volume":"41","author":"Hechtman","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib61","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41379-018-0118-3","article-title":"Molecular characterization of cancers with NTRK gene fusions","volume":"32","author":"Gatalica","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib62","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/jclinpath-2018-205679","article-title":"Testing algorithm for identification of patients with TRK fusion cancer","volume":"72","author":"Penault-Llorca","year":"2019","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib63","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1097\/PAS.0000000000001366","article-title":"Pan-TRK immunohistochemistry","volume":"43","author":"Harrison","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib64","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib65","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1002\/cncr.30102","article-title":"Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: an emerging opportunity for anti-HER2 targeted therapies","volume":"122","author":"Ross","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib66","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1158\/1078-0432.CCR-17-0900","article-title":"Neratinib efficacy and circulating tumor DNA detection of HER2 mutations in HER2 nonamplified metastatic breast cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib67","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib68","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Bose","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib69","doi-asserted-by":"crossref","first-page":"6375956","DOI":"10.1155\/2020\/6375956","article-title":"Somatic mutations in HER2 and implications for current treatment paradigms in HER2-positive breast cancer","volume":"2020","author":"Gaibar","year":"2020","journal-title":"J Oncol"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib70","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10549-017-4415-1","article-title":"Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers","volume":"166","author":"Santa-Maria","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib71","doi-asserted-by":"crossref","first-page":"26414","DOI":"10.18632\/oncotarget.14476","article-title":"Genomic mutation-driven metastatic breast cancer therapy: a single center experience","volume":"8","author":"Yuan","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib72","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ctrv.2019.01.004","article-title":"Circulating tumor DNA analysis in breast cancer: is it ready for prime-time?","volume":"73","author":"Buono","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib73","series-title":"Alpelisib + fulvestrant for advanced breast cancer: subgroup analyses from the phase III SOLAR-1 trial","first-page":"GS3-08","author":"Juric","year":"2018"},{"key":"10.1016\/j.jmoldx.2021.07.026_bib74","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157821002622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157821002622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:16:37Z","timestamp":1761502597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157821002622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":74,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1525157821002622"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2021.07.026","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Testing in Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2021.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}